Epoprostenol Injection 1.5 mg/via; Suppliers & Bulk Manufacturers

Available Forms: Injection

Available Strengths: 1.5 mg/via;

Reference Brands: Flolan®(Us & Eu)

Category: Orphan Drugs

Epoprostenol infusion solution is a prostacyclin analogue that dilates pulmonary blood vessels, reducing blood pressure in PAH. It inhibits platelet aggregation, preventing blood clots. Benefits include improved exercise capacity, symptom relief, and enhanced quality of life in PAH patients, especially those with advanced disease.

Product Description: Epoprostenol infusion solution, marketed as Flolan® in the US and EU, is approved for pulmonary arterial hypertension. Regulatory dossiers include extensive clinical data, manufacturing details, and safety profiles submitted to FDA and EMA, supporting its approval for continued use. The solution is administered via continuous IV infusion, with dosing tailored individually. These dossiers ensure high-quality standards and efficacy. For in-depth insights into regulatory submissions, dossier requirements, and market approvals, visit PharmaTradz, your trusted source for pharmaceutical regulatory updates and industry insights.